Comparison · NCT02558296-sae
Bexagliflozin Tablets, 20 mg vs Placebo Tablets: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Bexagliflozin Tablets, 20 mg vs Placebo Tablets: serious adverse events. Trial comparisons, record NCT02558296-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02558296-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.33 | 0.303 | 0.357 | wilson | |
| Risk in group 2 | 0.367 | 0.328 | 0.407 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0373 | -0.0858 | 0.0103 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.898 | 0.784 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | 0.848 | 0.687 | 1.05 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Bexagliflozin Tablets, 20 mg than on Placebo Tablets | 26.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Bexagliflozin Tablets, 20 mg | Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.~Bexagliflozin: 20 mg, tablet | 373 | 1,132 | EG000 |
| Group 2 | Placebo Tablets | Each subject will receive placebo (inactive tablet) once daily for the duration of the study.~Placebo: 20 mg tablet to match active comparator | 208 | 567 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data were collected from the first dose to the last day of follow up (4 weeks after the End of Treatment visit, an average of 127 weeks)
Source ClinicalTrials.gov
Trial
- Title
- Bexagliflozin Efficacy and Safety Trial
- NCT number
- NCT02558296
- Phases
- PHASE3
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Bexagliflozin, Placebo
- Lead sponsor
- Theracos
- Results first posted
- 2021-07-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02558296?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02558296-sae